{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:11:58Z","timestamp":1774397518022,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Fondo de Investigaciones Sanitarias (FIS)","award":["PI13\/00687"],"award-info":[{"award-number":["PI13\/00687"]}]},{"name":"Fondo de Investigaciones Sanitarias (FIS)","award":["PI16\/00490"],"award-info":[{"award-number":["PI16\/00490"]}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund (FEDER)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anaerobe"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.anaerobe.2017.10.002","type":"journal-article","created":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T01:46:21Z","timestamp":1507772781000},"page":"269-272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Rifaximin-resistant Clostridium difficile strains isolated from symptomatic patients"],"prefix":"10.1016","volume":"48","author":[{"given":"E.","family":"Reigadas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Mu\u00f1oz-Pacheco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"V\u00e1zquez-Cuesta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Alcal\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Bouza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.anaerobe.2017.10.002_bib1","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1749-6632.2010.05863.x","article-title":"Clostridium difficile: progress and challenges","volume":"1213","author":"Bartlett","year":"2010","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.anaerobe.2017.10.002_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/nrgastro.2010.190","article-title":"Clostridium difficile infection: epidemiology, risk factors and management","volume":"8","author":"Ananthakrishnan","year":"2011","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.anaerobe.2017.10.002_bib3","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1469-0691.2011.03571.x","article-title":"The economic burden of Clostridium difficile","volume":"18","author":"McGlone","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.anaerobe.2017.10.002_bib4","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1093\/jac\/dkr377","article-title":"A\u00a0randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection","volume":"66","author":"Garey","year":"2011","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.anaerobe.2017.10.002_bib5","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1086\/511870","article-title":"Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin","volume":"44","author":"Johnson","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.anaerobe.2017.10.002_bib6","series-title":"Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard M11\u2013A8","author":"Clinical and Laboratory Standards Institute","year":"2012"},{"key":"10.1016\/j.anaerobe.2017.10.002_bib7","series-title":"Performance Standards for Antimicrobial Susceptibility Testing: 24th Informational Supplement M100\u2013s24","author":"C.a.L.S. Institute","year":"2014"},{"key":"10.1016\/j.anaerobe.2017.10.002_bib8","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1128\/JCM.37.2.461-463.1999","article-title":"PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes","volume":"37","author":"Stubbs","year":"1999","journal-title":"J.\u00a0Clin. Microbiol."},{"key":"10.1016\/j.anaerobe.2017.10.002_bib9","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1086\/651706","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA)","volume":"31","author":"Cohen","year":"2010","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"10.1016\/j.anaerobe.2017.10.002_bib10","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A\u00a0new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J.\u00a0Chronic Dis."},{"key":"10.1016\/j.anaerobe.2017.10.002_bib11","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1001\/archinte.1962.03620240029006","article-title":"Gram-negative bacteremia: I. Etiology and ecology","volume":"110","author":"WR","year":"1962","journal-title":"Arch. Intern Med."},{"issue":"Suppl 2","key":"10.1016\/j.anaerobe.2017.10.002_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/1469-0691.12418","article-title":"European society of clinical microbiology and infectious diseases: update of the treatment guidance document for Clostridium difficile infection","volume":"20","author":"Debast","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.anaerobe.2017.10.002_bib13","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000007297","article-title":"In\u00a0vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species","volume":"46","author":"Marchese","year":"2000","journal-title":"Chemotherapy"},{"key":"10.1016\/j.anaerobe.2017.10.002_bib14","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1128\/AAC.01623-06","article-title":"In\u00a0vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004","volume":"51","author":"Hecht","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.anaerobe.2017.10.002_bib15","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/jcp.2009.071688","article-title":"In\u00a0vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston","volume":"63","author":"Jiang","year":"2010","journal-title":"Tex. J. Clin. Pathol."},{"key":"10.1016\/j.anaerobe.2017.10.002_bib16","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1128\/AAC.00342-08","article-title":"Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile","volume":"52","author":"O'Connor","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.anaerobe.2017.10.002_bib17","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.anaerobe.2010.09.002","article-title":"Antimicrobial susceptibility and heteroresistance in Chinese Clostridium difficile strains","volume":"16","author":"Huang","year":"2010","journal-title":"Anaerobe"},{"key":"10.1016\/j.anaerobe.2017.10.002_bib18","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1086\/596315","article-title":"High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital","volume":"48","author":"Curry","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.anaerobe.2017.10.002_bib19","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1128\/JCM.05100-11","article-title":"Divergent rifamycin susceptibilities of Clostridium difficile strains in Canada and Italy and predictive accuracy of rifampin Etest for rifamycin resistance","volume":"49","author":"Miller","year":"2011","journal-title":"J.\u00a0Clin. Microbiol."},{"key":"10.1016\/j.anaerobe.2017.10.002_bib20","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1099\/jmm.0.028571-0","article-title":"Rifaximin disc diffusion test for in\u00a0vitro susceptibility testing of Clostridium difficile","volume":"60","author":"Huhulescu","year":"2011","journal-title":"J.\u00a0Med. Microbiol."},{"key":"10.1016\/j.anaerobe.2017.10.002_bib21","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1093\/jac\/dkr292","article-title":"Multidrug resistance in European Clostridium difficile clinical isolates","volume":"66","author":"Spigaglia","year":"2011","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.anaerobe.2017.10.002_bib22","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.3389\/fmicb.2016.01621","article-title":"Molecular epidemiology and antimicrobial susceptibility of Clostridium difficile isolates from a university teaching hospital in China","volume":"7","author":"Cheng","year":"2016","journal-title":"Front. Microbiol."}],"container-title":["Anaerobe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107599641730197X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107599641730197X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T17:05:33Z","timestamp":1603127133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107599641730197X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":22,"alternative-id":["S107599641730197X"],"URL":"https:\/\/doi.org\/10.1016\/j.anaerobe.2017.10.002","relation":{},"ISSN":["1075-9964"],"issn-type":[{"value":"1075-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rifaximin-resistant Clostridium difficile strains isolated from symptomatic patients","name":"articletitle","label":"Article Title"},{"value":"Anaerobe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anaerobe.2017.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}